Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 29, Issue 5, Pages 475-486Publisher
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2010.30.2554
Keywords
-
Categories
Funding
- ROCHE Diagnostics
Ask authors/readers for more resources
Molecular analyses of leukemic blasts from patients with acute myeloid leukemia (AML) have revealed a striking heterogeneity with regard to the presence of acquired gene mutations and changes in gene and microRNA expression. Multiple submicroscopic genetic alterations with prognostic significance have been discovered. Application of gene- and microRNA profiling has identified genome-wide expression signatures that separate cytogenetic and molecular subsets of patients with AML into previously unrecognized biologic and/or prognostic subgroups. These and similar future findings are likely to have a major impact on the clinical management of AML because many of the identified genetic alterations not only represent independent prognosticators, but also may constitute targets for specific therapeutic intervention. In this report, we review genetic findings in AML and discuss their clinical implications. J Clin Oncol 29:475-486. (c) 2011 by American Society of Clinical Oncology
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available